Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Flatiron Health announced its first Panoramic datasets for prostate cancer patients in the UK and Germany, encompassing records of nearly 400,000 patients across three countries. The datasets leverage AI and large language models to provide unified real-world evidence for cancer research.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06724159 |
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors. |
RECRUITING | |
| NCT02045368 |
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R |
COMPLETED | PHASE1 |
| NCT01851395 |
Rapid Autopsy and Procurement of Cancer Tissue |
TERMINATED |
